Kabra Drugs Ltd Stock Price Today (NSE: KABRADG)
Fundamental Score
Kabra Drugs Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Kabra Drugs Ltd share price today is ₹24.58, down 3.19% on NSE/BSE as of 30 March 2026. Kabra Drugs Ltd (KABRADG) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹74.23 (Cr). The 52-week high for KABRADG share price is ₹35.52 and the 52-week low is ₹10.56. At a P/E ratio of 62.38x, KABRADG is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of -8.47% and a debt-to-equity ratio of 0.02.
Kabra Drugs Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Kabra Drugs Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Kabra Drugs Share Price Analysis: A Critical Look at Profitability
The pharmaceutical industry, while demonstrating resilience, is witnessing heightened competition and margin pressures, necessitating strategic financial management. This analysis examines Kabra Drugs share price (₹30.690001 as of last close) in light of its key financial metrics and peer performance. Of particular interest is the company's current Price-to-Earnings (PE) ratio of 62.38 and a Return on Capital Employed (ROCE) of -7.82%. This preliminary financial analysis is part of a larger 80-parameter fundamental audit verified by Sweta Mishra.
A high PE ratio suggests that investors have high expectations for future earnings growth. However, when coupled with a negative ROCE, it raises concerns about the sustainability of this valuation. ROCE measures a company's profitability relative to the capital employed. A negative ROCE, as seen with Kabra Drugs Ltd, indicates that the company is currently destroying value, as the return generated from its capital investments is insufficient to cover the cost of that capital. This negatively impacts the company's economic moat, making it harder to defend market share or achieve a sustainable competitive advantage.
Comparing Kabra Drugs Ltd with its peers provides further context.
Mankind Pharma Ltd, for instance, likely boasts a stronger management track record and potentially more efficient capital allocation, reflected in its ROCE and likely a more sustainable growth trajectory. While a direct comparison requires detailed financial data, the stark contrast in ROCE between Kabra Drugs Ltd and potentially more profitable peers underscores the challenges the company faces in optimizing its operations and generating shareholder value.The high PE ratio juxtaposed against the negative ROCE suggests the market may be anticipating a turnaround. However, realizing this potential will depend on Kabra Drugs Ltd implementing effective strategies to improve its capital efficiency, manage costs, and generate profitable growth. This analysis is purely observational and does not constitute any buy/sell recommendation.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Kabra Drugs Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of KABRADG across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Robust Profit Growth (560.00%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Conservative Debt Levels (D/E: 0.02)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
6 factors identified
Below-Average Return on Equity (-8.47%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-7.82%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 62.38x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Negative Free Cash Flow (₹-5.70 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Low Promoter Commitment (0.00%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Kabra Drugs Ltd Financial Statements
Comprehensive financial data for Kabra Drugs Ltd including income statement, balance sheet and cash flow
About KABRADG (Kabra Drugs Ltd)
Kabra Drugs Ltd is a dormant entity in the pharmaceutical sector, currently holding no active operational functions. Historically, Kabra Drugs Ltd participated in the manufacturing... and commercial exchange of pharmaceutical related goods, though these activities have ceased. The company's original ambition focused on permaculture, a sustainable agricultural system, hinting at an earlier diversification strategy into eco-friendly practices. This suggests a potential for incorporating environmentally conscious manufacturing processes should the company choose to reactivate. Established in 1989, Kabra Drugs Ltd has maintained its headquarters in Chennai, India, as its registered base. While currently inactive, the company's registration as a pharmaceutical entity provides a potential framework for future development within the industry. The existing infrastructure and knowledge base, however outdated, could offer a foundation for re-entry into the market, either through internal restructuring or external collaborations. The company's long-standing presence, even in dormancy, suggests a level of legacy and brand awareness that could be leveraged in any future endeavors. The current state of Kabra Drugs Ltd necessitates a significant reevaluation of its business model and strategic direction should it seek to revitalize its operations. Market analysis, investment in updated technology, and a renewed focus on regulatory compliance would be essential to compete effectively in the modern pharmaceutical landscape. The shift from active engagement to dormancy represents a turning point in the company's history, demanding bold leadership and innovative strategies to navigate the challenges and opportunities that lie ahead.
Company Details
Key Leadership
KABRADG Share Price: Frequently Asked Questions
What is the current share price of Kabra Drugs Ltd (KABRADG)?
As of 30 Mar 2026, 12:03 pm IST, Kabra Drugs Ltd share price is ₹24.58. The KABRADG stock has a market capitalisation of ₹74.23 (Cr) on NSE/BSE.
Is KABRADG share price Overvalued or Undervalued?
KABRADG share price is currently trading at a P/E ratio of 62.38x, compared to the industry average of 31.77x. Based on this relative valuation, the Kabra Drugs Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of KABRADG share price?
The 52-week high of KABRADG share price is ₹35.52 and the 52-week low is ₹10.56. These values are updated daily from NSE/BSE price data.
What factors affect the Kabra Drugs Ltd share price?
Key factors influencing KABRADG share price include quarterly earnings growth (Sales Growth: N/A%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Kabra Drugs Ltd a good stock for long-term investment?
Kabra Drugs Ltd shows a 5-year Profit Growth of N/A% and an ROE of -8.47%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.02 before investing in KABRADG shares.
How does Kabra Drugs Ltd compare with its industry peers?
Kabra Drugs Ltd competes with major peers in the Pharmaceuticals. Investors should compare KABRADG share price P/E of 62.38x and ROE of -8.47% against the industry averages to determine competitive standing.
What is the P/E ratio of KABRADG and what does it mean?
KABRADG share price has a P/E ratio of 62.38x compared to the industry average of 31.77x. Investors pay ₹62 for every ₹1 of annual earnings.
How is KABRADG performing according to Bull Run's analysis?
KABRADG has a Bull Run fundamental score of 10.5/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does KABRADG belong to?
KABRADG operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Kabra Drugs Ltd share price.
What is Return on Equity (ROE) and why is it important for KABRADG?
KABRADG has an ROE of -8.47%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Kabra Drugs Ltd generates profits from shareholders capital.
How is KABRADG debt-to-equity ratio and what does it indicate?
KABRADG has a debt-to-equity ratio of 0.02, which indicates conservative financing with low financial risk.
What is KABRADG dividend yield and is it a good dividend stock?
KABRADG offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Kabra Drugs Ltd shares.
How has KABRADG share price grown over the past 5 years?
KABRADG has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in KABRADG and why does it matter?
Promoters hold 0.00% of KABRADG shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Kabra Drugs Ltd.
What is KABRADG market capitalisation category?
KABRADG has a market capitalisation of ₹74 crores, placing it in the Small-cap category.
How volatile is KABRADG stock?
KABRADG has a beta of N/A. A beta > 1 suggests the Kabra Drugs Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is KABRADG operating profit margin trend?
KABRADG has a 5-year average Operating Profit Margin (OPM) of N/A%, indicating the company's operational efficiency.
How is KABRADG quarterly performance?
Recent quarterly performance shows Kabra Drugs Ltd YoY Sales Growth of N/A% and YoY Profit Growth of 560.00%.
What is the institutional holding pattern in KABRADG?
KABRADG has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Kabra Drugs Ltd stock.